Clinical Pharmacy Practice Exam (Answered)
2023/2024, 300 Questions And Correct Answers
1. It refers to the responsible provision of drug therapy to achieve definite outcomes that are
intended to improve a patient’s quality of life
A. Professional-patient’s relationship
B. Therapeutic drug monitoring
C. Drug therapy assessment
D. Pharmaceutical care
E. Formal documentation
2. It involves measuring direct and indirect costs attributable to a specific disease
A. Cost-of-Illness Evaluation
B. Cost-Effectiveness Analysis
C. Cost-Minimization Analysis
D. Cost-Utility Analysis
E. Cost-Benefit Analysis
3. The method that allows for the identification, measurement, and comparison of the benefits
and costs of a program or treatment alternative
A. Cost-of-Illness Evaluation
B. Cost-Effectiveness Analysis
C. Cost-Minimization Analysis
D. Cost-Utility Analysis
E. Cost-Benefit Analysis
4. The method that involves the determination of the least costly alternative when
comparing two or more treatment alternatives
A. Cost-of-Illness Evaluation
B. Cost-Effectiveness Analysis
C. Cost-Minimization Analysis
D. Cost-Utility Analysis
E. Cost-Benefit Analysis
5. The method that integrates the patient preferences and health-related quality of life
A. Cost-of-Illness Evaluation
B. Cost-Effectiveness Analysis
C. Cost-Minimization Analysis
D. Cost-Utility Analysis
E. Cost-Benefit Analysis
6. A way of summarizing the health benefits and resources used by competing health care
programs so that policy makers can choose among them
A. Cost-of-Illness Evaluation
B. Cost-Effectiveness Analysis
C. Cost-Minimization Analysis
D. Cost-Utility Analysis
E. Cost-Benefit Analysis
7. It refers to the value assigned to duration of life as modified by impairments, functional states,
perceptions and social opportunities that are influenced by disease, injury, treatment or policy
A. Optimum health
B. Quality of life
C. Health outcomes
D. Responsiveness
E. Wellness of being
8. A study design in which neither the study subject nor the study staff is aware of which group
or intervention the subjects has been assigned
A. Randomized control trial
B. Crossover study
,B. Case control study
, C. Cohort study
D. meta-analysis
E. open-label trial
10. A retrospective or prospective follow-up study of exposed and non-exposed defined groups in
which a variable of interest is measured
A. Cross-sectional study
B. Case control study
C. Cross over study
D. Cohort study
E. open label trial
11. A trial comparing treatments in which participants, on completion of one treatment, are switched
to the other
A. Cross-sectional study
B. Cross over study
C. meta-analysis
D. open label trial
E. cohort study
12. A study that examines the presence or absence of a disease and other variable in a defined
population and the potential risk factor at a particular point in time or time-interval
A. Cross-sectional study
B. Cohort study
C. case control study
D. cross over study
E. case series
13. Which of the following best describes the neonates?
A. those who are 1 month to 1 year of age
B. those who are 1 year to 12 years of age
C. those who are 12 to 16 years of age
D. those between 1 day and 1 month
E. those born before 32 weeks of gestational age
14. Which of the following best describes the infant?
A. those who are 1 month to 1 year of age
B. those who are 1 year to 12 years of age
C. those who are 12 to 16 years of age
D. those between 1 day and 1 month
E. those born before 32 weeks of gestational age
15. Clinical manifestation of Gray Baby Syndrome include:
I. Characteristic gray color III. Hypertension
II. Abdominal distention IV. Progressive shock
A. I only
B. I and IV only
C. I, II and III only
D. I, II and IV only
E. I and III only
16. Which of the following is associated with the use of thalidomide?
I. Polyneuritis III. Limb deformities
II. Mental retardation
A. I only
B. I, II and III only
C. II and III only
D. III only
E. I and III only
17. Factors that increase the risk of drug-related problems in the elderly include:
I. Polypharmacy III. Medication adherence
II. Inappropriate prescribing IV. Multiple diseases
A. I and II only
B. I, II and III only
, II. Mental acuity IV. Reliance on a caregiver for the history
2023/2024, 300 Questions And Correct Answers
1. It refers to the responsible provision of drug therapy to achieve definite outcomes that are
intended to improve a patient’s quality of life
A. Professional-patient’s relationship
B. Therapeutic drug monitoring
C. Drug therapy assessment
D. Pharmaceutical care
E. Formal documentation
2. It involves measuring direct and indirect costs attributable to a specific disease
A. Cost-of-Illness Evaluation
B. Cost-Effectiveness Analysis
C. Cost-Minimization Analysis
D. Cost-Utility Analysis
E. Cost-Benefit Analysis
3. The method that allows for the identification, measurement, and comparison of the benefits
and costs of a program or treatment alternative
A. Cost-of-Illness Evaluation
B. Cost-Effectiveness Analysis
C. Cost-Minimization Analysis
D. Cost-Utility Analysis
E. Cost-Benefit Analysis
4. The method that involves the determination of the least costly alternative when
comparing two or more treatment alternatives
A. Cost-of-Illness Evaluation
B. Cost-Effectiveness Analysis
C. Cost-Minimization Analysis
D. Cost-Utility Analysis
E. Cost-Benefit Analysis
5. The method that integrates the patient preferences and health-related quality of life
A. Cost-of-Illness Evaluation
B. Cost-Effectiveness Analysis
C. Cost-Minimization Analysis
D. Cost-Utility Analysis
E. Cost-Benefit Analysis
6. A way of summarizing the health benefits and resources used by competing health care
programs so that policy makers can choose among them
A. Cost-of-Illness Evaluation
B. Cost-Effectiveness Analysis
C. Cost-Minimization Analysis
D. Cost-Utility Analysis
E. Cost-Benefit Analysis
7. It refers to the value assigned to duration of life as modified by impairments, functional states,
perceptions and social opportunities that are influenced by disease, injury, treatment or policy
A. Optimum health
B. Quality of life
C. Health outcomes
D. Responsiveness
E. Wellness of being
8. A study design in which neither the study subject nor the study staff is aware of which group
or intervention the subjects has been assigned
A. Randomized control trial
B. Crossover study
,B. Case control study
, C. Cohort study
D. meta-analysis
E. open-label trial
10. A retrospective or prospective follow-up study of exposed and non-exposed defined groups in
which a variable of interest is measured
A. Cross-sectional study
B. Case control study
C. Cross over study
D. Cohort study
E. open label trial
11. A trial comparing treatments in which participants, on completion of one treatment, are switched
to the other
A. Cross-sectional study
B. Cross over study
C. meta-analysis
D. open label trial
E. cohort study
12. A study that examines the presence or absence of a disease and other variable in a defined
population and the potential risk factor at a particular point in time or time-interval
A. Cross-sectional study
B. Cohort study
C. case control study
D. cross over study
E. case series
13. Which of the following best describes the neonates?
A. those who are 1 month to 1 year of age
B. those who are 1 year to 12 years of age
C. those who are 12 to 16 years of age
D. those between 1 day and 1 month
E. those born before 32 weeks of gestational age
14. Which of the following best describes the infant?
A. those who are 1 month to 1 year of age
B. those who are 1 year to 12 years of age
C. those who are 12 to 16 years of age
D. those between 1 day and 1 month
E. those born before 32 weeks of gestational age
15. Clinical manifestation of Gray Baby Syndrome include:
I. Characteristic gray color III. Hypertension
II. Abdominal distention IV. Progressive shock
A. I only
B. I and IV only
C. I, II and III only
D. I, II and IV only
E. I and III only
16. Which of the following is associated with the use of thalidomide?
I. Polyneuritis III. Limb deformities
II. Mental retardation
A. I only
B. I, II and III only
C. II and III only
D. III only
E. I and III only
17. Factors that increase the risk of drug-related problems in the elderly include:
I. Polypharmacy III. Medication adherence
II. Inappropriate prescribing IV. Multiple diseases
A. I and II only
B. I, II and III only
, II. Mental acuity IV. Reliance on a caregiver for the history
